NASDAQ:SYNH - Syneos Health Stock Price, Forecast & News

Syneos Health's stock was trading at $57.30 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SYNH shares have decreased by 27.4% and is now trading at $41.60. View which stocks have been mosted impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Syneos Health.

Syneos Health is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Syneos Health.

Syneos Health Inc (NASDAQ:SYNH) posted its quarterly earnings data on Thursday, February, 20th. The company reported $1.03 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.01 by $0.02. The company had revenue of $1.21 billion for the quarter, compared to analysts' expectations of $1.19 billion. Syneos Health had a net margin of 2.81% and a return on equity of 10.12%. Syneos Health's revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.95 EPS. View Syneos Health's earnings history.

Syneos Health updated its FY20 earnings guidance on Thursday, February, 20th. The company provided earnings per share guidance of $3.58-3.78 for the period, compared to the Thomson Reuters consensus estimate of $3.65. The company issued revenue guidance of $4.88-5.00 billion, compared to the consensus revenue estimate of $4.94 billion.

10 analysts have issued 1-year price targets for Syneos Health's shares. Their forecasts range from $52.00 to $82.00. On average, they expect Syneos Health's share price to reach $68.00 in the next twelve months. This suggests a possible upside of 63.5% from the stock's current price. View analysts' price targets for Syneos Health.

News headlines about SYNH stock have been trending extremely negative recently, according to InfoTrie. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Syneos Health earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutSyneos Health.

Syneos Health saw a drop in short interest during the month of March. As of March 13th, there was short interest totaling 6,199,900 shares, a drop of 6.3% from the February 27th total of 6,620,000 shares. Based on an average daily trading volume, of 1,569,000 shares, the days-to-cover ratio is presently 4.0 days. Currently, 10.0% of the company's shares are short sold. View Syneos Health's Current Options Chain.

Some companies that are related to Syneos Health include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), PPD (PPD), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Precigen (PGEN), Intrexon (XON), Auxly Cannabis Group (CBWTF), Anavex Life Sciences (AVXL) and Luna Innovations (LUNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Alibaba Group (BABA), AT&T (T), Square (SQ), Netflix (NFLX), Constellation Brands (STZ), UnitedHealth Group (UNH), Verizon Communications (VZ), JD.Com (JD) and Micron Technology (MU).

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Syneos Health's stock is owned by many different institutional and retail investors. Top institutional investors include ArrowMark Colorado Holdings LLC (2.23%), State Street Corp (1.92%), Bank of New York Mellon Corp (1.51%), Goldman Sachs Group Inc. (1.44%), Boston Partners (1.25%) and GW&K Investment Management LLC (1.05%). Company insiders that own Syneos Health stock include Alistair Macdonald, H Lee Equity Fund Vi Thomas, Jason M Meggs, Jonathan Olefson and Paul Colvin. View institutional ownership trends for Syneos Health.

SYNH stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Principal Financial Group Inc., Prudential Financial Inc., Sei Investments Co., AXA, Goldman Sachs Group Inc., Boston Partners, and Rothschild & Co. Asset Management US Inc.. View insider buying and selling activity for Syneos Health.

SYNH stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Norges Bank, Jennison Associates LLC, Hennessy Advisors Inc., Barclays PLC, Knights of Columbus Asset Advisors LLC, Hawk Ridge Capital Management LP, and ArrowMark Colorado Holdings LLC. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs, Jonathan Olefson, and Paul Colvin. View insider buying and selling activity for Syneos Health.

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SYNH stock can currently be purchased for approximately $41.60.

Syneos Health has a market capitalization of $4.34 billion and generates $4.68 billion in revenue each year. The company earns $131.26 million in net income (profit) each year or $2.83 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe. View additional information about Syneos Health.

The official website for Syneos Health is http://www.syneoshealth.com/.

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]